-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
▎WuXi AppTec Content Team Editor On January 25, 2022, Leyden Laboratories announced the completion of a $140 million Series B financing
.
Funds from this round will be used to support the growth of Leyden Labs’ platform, product portfolio and team
.
The company's platform is based on two innovative concepts: broad protection against known viruses, new variants, and emerging viruses; and protection at the "gateways" of virus invasion, such as the mucous membranes in the nose and throat
.
Founded in 2020, Leyden Labs' technology platform supports the development of broadly neutralizing antibodies delivered via an intranasal spray
.
Prevention of coronavirus family and other respiratory diseases
.
Specifically, millions of unknown viruses in nature can be divided into dozens of virus families
.
By targeting the commonalities of these virus families, researchers are able to develop protective therapies against the entire virus family, including unknown virus variants
.
Leyden Labs is currently focusing on respiratory viruses with the greatest potential to cause pandemics, such as influenza and coronaviruses
.
These viruses can be transmitted through the air, so the nasal cavity is the first line of virus invasion
.
Leyden Labs aims to develop an intranasal spray that provides immediate protection from infection and prevents spreading the virus to others
.
Because the product itself is a neutralizing antibody, they do not rely on the body's immune system to function, so it can effectively protect high-risk infection groups, such as the elderly and immunocompromised people
.
Mr.
Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, Mapping the Content Team at WuXi AppTec, said: "This round of financing is a testament to investors' trust in us that Leyden Labs' platform can generate cornerstone products for the fight against respiratory diseases.
COVID
-
19 Lessons from the outbreak show the need to expand our arsenal of tools to combat current and future virus outbreaks
.
” Reference: [1] Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses.
Retrieved January 25, 2022, from https:// Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
.
Funds from this round will be used to support the growth of Leyden Labs’ platform, product portfolio and team
.
The company's platform is based on two innovative concepts: broad protection against known viruses, new variants, and emerging viruses; and protection at the "gateways" of virus invasion, such as the mucous membranes in the nose and throat
.
Founded in 2020, Leyden Labs' technology platform supports the development of broadly neutralizing antibodies delivered via an intranasal spray
.
Prevention of coronavirus family and other respiratory diseases
.
Specifically, millions of unknown viruses in nature can be divided into dozens of virus families
.
By targeting the commonalities of these virus families, researchers are able to develop protective therapies against the entire virus family, including unknown virus variants
.
Leyden Labs is currently focusing on respiratory viruses with the greatest potential to cause pandemics, such as influenza and coronaviruses
.
These viruses can be transmitted through the air, so the nasal cavity is the first line of virus invasion
.
Leyden Labs aims to develop an intranasal spray that provides immediate protection from infection and prevents spreading the virus to others
.
Because the product itself is a neutralizing antibody, they do not rely on the body's immune system to function, so it can effectively protect high-risk infection groups, such as the elderly and immunocompromised people
.
Mr.
Koenraad Wiedhaup, Co-Founder and CEO of Leyden Labs, Mapping the Content Team at WuXi AppTec, said: "This round of financing is a testament to investors' trust in us that Leyden Labs' platform can generate cornerstone products for the fight against respiratory diseases.
COVID
-
19 Lessons from the outbreak show the need to expand our arsenal of tools to combat current and future virus outbreaks
.
” Reference: [1] Leyden Labs Raises $200M in 2021 for a New Approach to Combat Viruses.
Retrieved January 25, 2022, from https:// Disclaimer: The WuXi AppTec content team focuses on introducing global biomedical health research progress
.
This article is for information exchange purposes only, and the views expressed in this article do not represent WuXi AppTec's position, nor do they represent WuXi AppTec's support or opposition to the views expressed in this article
.
This article is also not a treatment plan recommendation
.
For guidance on treatment options, please visit a regular hospital
.
